Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations
I'm PortAI, I can summarize articles.
Psyence BioMed has made a strategic equity investment in PsyLabs, enhancing its African ibogaine operations. This move positions Psyence BioMed as the sole publicly listed psychedelics company with active operations in Africa, strengthening its supply chain and providing early access to pipeline products and intellectual property development amid rising global demand for psychedelic APIs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments